TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Dirk Eulberg
Vice President Project Management at NOXXON Pharma AG

Profile

Dirk Eulberg, PhD, MBA, serves as Vice President for Project Management and Preclinical Development at NOXXON Pharma AG in Berlin, Germany. He joined the company in 2000 to establish an automated process for discovery of Spiegelmers and has since then been responsible for the development of Spiegelmers from lead identification and optimization via pharmacological profiling and formal non-clinical development into the clinic until Proof-of-Concept in patients. Dirk studied biology in Stuttgart where he received his PhD degree in 1997, and business administration in Potsdam from 2009-2011.

Dirk Eulberg's Network

Agenda Sessions

  • Clinical Development of CXCL12 Inhibiting L-RNA Aptamer NOX-A12 (Olaptesed Pegol)

    , 11:00

Speakers at this event